Status:

ACTIVE_NOT_RECRUITING

Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS)

Lead Sponsor:

Centre Leon Berard

Conditions:

Non-Resectable Pancreas Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This is a phase I/II, multicenter trial for patients with locally advanced and unresectable pancreatic tumours : * A Phase I evaluating the tolerance of intraoperative High Intensity Focused Ultrasou...

Detailed Description

The PULS study is designed for patients with a locally advanced tumour of the pancreas (known as pancreatic adenocarcinoma) that has previously been treated with several cycles of chemotherapy and can...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years at the day of consenting to the study
  • Patient with histologically confirmed locally advanced (unresectable) pancreatic adenocarcinoma according to the National Comprehensive Cancer Network (NCCN) 2020 classification
  • Unifocal pancreatic lesion with a maximum diameter of 4 cm
  • Non-progressive disease after 4 months of first-line chemotherapy or after 2 months of chemotherapy in case of limiting toxicity contraindicating continuation of chemotherapy;
  • Preoperative imaging including CT-scan, MRI of the liver and Positron Emission Computed Tomography scan (PET-CT scan) (except for absolute medical contraindications), within 4 weeks prior to HIFU treatment
  • Eastern Cooperative Oncology Group performance status ≤ 2
  • Adequate hematologic parameters defined by platelets ≥ 100 Giga/l and hemoglobin ≥ 8 g/dl
  • Ability to understand and willingness for follow-up visits
  • Patient affiliated to a health insurance scheme (or beneficiary of such a scheme)
  • Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment

Exclusion

  • Local recurrence of previously operated pancreatic cancer
  • Metastatic pancreatic carcinoma
  • History of major pancreatic resection
  • Chemotherapy completed less than 2 weeks ago
  • History of radiotherapy to the pancreas
  • Pregnant women
  • Possibility of R0 resection with venous reconstruction
  • Inability to undergo study follow-up for geographical, social or psychological reasons
  • Patient requiring tutorship or curatorship or patient deprived of liberty
  • Patient under psychiatric care against his wishes

Key Trial Info

Start Date :

June 25 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2030

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT06211933

Start Date

June 25 2024

End Date

February 1 2030

Last Update

January 8 2026

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHU Estaing

Clermont-Ferrand, Auvergne-Rhône-Alpes, France, 63003

2

Centre Léon Bérard

Lyon, Auvergne-Rhône-Alpes, France, 69008